Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson(Cornell University), David R. Nelson(University of Florida), Eugene R. Schiff(University of Miami), Michael Bennett(Associates Research), Stuart C. Gordon(Henry Ford Health System), William T. Symonds(Gilead Sciences (United States)), Jordan J. Feld(University of Toronto), M. Rodríguez‐Torres(Puerto Rico Community Foundation), Mark Sulkowski(Johns Hopkins University), Gregory T. Everson(University of Colorado Denver), Di An(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Eric M. Yoshida(University of British Columbia), Eric Lawitz(The University of Texas at San Antonio Health Science Center), G. Mani Subramanian(National Institutes of Health), Kris V. Kowdley(Washington State University Spokane), M. Lin(Gilead Sciences (United States)), M. Tarek Al-Assi(Texas Digestive Disease Consultants), Diana M. Brainard(Gilead Sciences (United States)), Stephen Pianko(Monash Medical Centre), Mitchell L. Shiffman(Bon Secours Health System), John McNally(Gilead Sciences (United States)), Keyur Patel(Duke University)
Cited by 1,082
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k